KKL 顾客使用本产品发表的 0 篇科研文献

Fanotaprim is a dihydrofolate reductase (DHFR) inhibitor with IC₅₀s of 1.57 and 308 nM for tgDHFR (Toxoplasma gondii DHFR) and hDHFR (human DHFR), respectively. Fanotaprim has the potential for the research of toxoplasmosis.

Fanotaprim shows parasiticidal and antiproliferative effects with EC₅₀s of 13 and 7300 nM against the type I RH strain of T. gondii and MCF-7 cells, respectively.
Fanotaprim shows ability to inhibit the growth of T. gondii strains in vitro with EC₅₀s ranging 7.6~ 29.8 nM (GT1, ME49, CTG, RUB and VAND).

Fanotaprim (1-10 mg/kg; p.o.; daily; beginning on day 1 through day 7) shows highly effective in control of acute infection by highly virulent strains of T. gondii in the murine model.
Fanotaprim (1mg/kg; i.v; mouse) shows C_L, V_d, and t_1/2 values of 10.6 mL/min/kg, 1.14 L/kg, and 3.9 hours, respectively.
Fanotaprim (0.83 mg/kg; p.o; mouse) shows F, C_max, T_max, and AUC_0-last of 47.3%, 178 ng/mL, 0.05 hours and 750 ng h/mL, respectively.

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.